January 7, 2008 – CoMentis, Inc., a privately held biopharmaceutical company, announced that it has completed a Phase I study of its proprietary, orally bioavailable, small-molecule beta-secretase inhibitor, CTS-21166, which is being developed as a disease-modifying treatment for Alzheimer’s disease... CoMentis' Press Release-Friday, January 25, 2008
CoMentis , Proof-of-Activity-Data from its Phase I Study of Disease-Modifying Alzheimer’s Disease Therapy
January 7, 2008 – CoMentis, Inc., a privately held biopharmaceutical company, announced that it has completed a Phase I study of its proprietary, orally bioavailable, small-molecule beta-secretase inhibitor, CTS-21166, which is being developed as a disease-modifying treatment for Alzheimer’s disease... CoMentis' Press Release-
